A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Clinical trial NCT06439771 · RECRUITING

Trial details

NCT number: NCT06439771
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Breast Cancer

Start date: 2024-04-23
Primary completion: 2026-07-30
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.